243 related articles for article (PubMed ID: 30343272)
1. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Luna J; Boni J; Cuatrecasas M; Bofill-De Ros X; Núñez-Manchón E; Gironella M; Vaquero EC; Arbones ML; de la Luna S; Fillat C
Gut; 2019 Aug; 68(8):1465-1476. PubMed ID: 30343272
[TBL] [Abstract][Full Text] [Related]
2. The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Bai Z; Du Y; Cong L; Cheng Y
Gene; 2020 Oct; 758():144960. PubMed ID: 32687947
[TBL] [Abstract][Full Text] [Related]
3. Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A.
Zhao C; Wang D; Gao Z; Kan H; Qiu F; Chen L; Li H
Chem Biol Interact; 2020 Jan; 316():108913. PubMed ID: 31838052
[TBL] [Abstract][Full Text] [Related]
4. Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.
Guo X; Zhang D; Zhang X; Jiang J; Xue P; Wu C; Zhang J; Jin G; Huang Z; Yang J; Zhu X; Liu W; Xu G; Cui Z; Bao G
Tissue Cell; 2018 Dec; 55():63-70. PubMed ID: 30503061
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
6. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
7. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.
Kaistha BP; Honstein T; Müller V; Bielak S; Sauer M; Kreider R; Fassan M; Scarpa A; Schmees C; Volkmer H; Gress TM; Buchholz M
Br J Cancer; 2014 Oct; 111(9):1780-7. PubMed ID: 25137017
[TBL] [Abstract][Full Text] [Related]
8. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
11. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
14. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
15. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
17. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
18. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer.
Bailey JM; Alsina J; Rasheed ZA; McAllister FM; Fu YY; Plentz R; Zhang H; Pasricha PJ; Bardeesy N; Matsui W; Maitra A; Leach SD
Gastroenterology; 2014 Jan; 146(1):245-56. PubMed ID: 24096005
[TBL] [Abstract][Full Text] [Related]
19. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
20. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
